Our integrated analysis delineated the tumor ecosystem in post‐HAIC HCC for the first time, and demonstrated the therapeutic potential of combining HAIC with PD‐1 blockade, which may guide the development of precision medicine to benefit a wide range of patients. Here, PDCD1 is linked to hepatocellular carcinoma.